pGBI-161

N/A

Report date: 2025/01/26 17:38:28
NME

Base Information

Drug NamepGBI-161
Drug Alias Nameanti-SRC3, anti-EGFR and anti-KRAS triple-targeting shRNA (Gradalis/Strike Bio)triple oncongene-targeting shRNA (Gradalis/Strike Bio)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > short hairpin RNA
Mechanisms of ActionV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitorsNuclear receptor coactivator 3 inhibitorsEpidermal growth factor receptor erbB1 antagonists
TargetsNuclear receptor coactivator 3Epidermal growth factor receptor erbB1GTPase KRas
Therapy Area/IndicationsLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGradalis Inc
China Registration ClassN/A

Develop Information

Active CompaniesStrike BioGradalis Inc
Inactive CompaniesN/A
Active IndicationsLung Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A